Lung cancer comes in two main types: non-small cell and small cell. Each has different patterns, growth rates, and treatment needs. Smoking is the top risk factor, but…
Harry Erba, MD, PhD, Duke University, Durham, NC; Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY; Thomas Cluzeau, MD, PhD, Central University Hospital…
NEW YORK (Reuters Health) – The extent of resection and residual volume are independently tied to survival and recurrence after surgery for newly diagnosed glioblastoma, according to a…
By Will Boggs, MD NEW YORK (Reuters Health) – Temsirolimus does not improve progression-free survival in metastatic renal cell carcinoma (RCC) compared to standard treatment, according to results…
NEW YORK (Reuters Health) – In patients with potentially resectable colorectal liver metastases, the use of combined PET and CT imaging (PET-CT) identifies those with occult extrahepatic disease…
NEW YORK (Reuters Health) – Although trastuzumab is directed against the HER2 protein, patients with HER2-negative breast cancer may also benefit from adjuvant trastuzumab therapy, researchers report. They…
NEW YORK (Reuters Health) – How much an individual patient with esophageal cancer is likely to benefit, if at all, from chemoradiotherapy (CRT) before undergoing esophagectomy can be…
NEW YORK (Reuters Health) – A diagnosis of bladder cancer after an initial presentation with hematuria is often delayed in both men and women – but the delay…
NEW YORK (Reuters Health) – A preoperative MRI showing whether or not a rectal tumor encroaches on the circumferential resection margin (CRM) is a better predictor of recurrence…
Martin Lee, author of Smoke Signals, and director of Project CBD, explains why doctors may find themselves in a difficult position when patients come to them with questions about medical…
Martin Lee, author of Smoke Signals, and director of Project CBD, discusses the results of a University of Calgary study that found New Yorkers suffering from PTSD after the…
Nancy Simonian, MD, CEO, Syros Pharmaceuticals explains that by modulating components of super-enhancers, important genes that drive disease states may be able to be turned down. She references a recent…
